| Accession |
PRJCA010833 |
| Title |
Molecular profiling of the clinical response of liver cancer patients to combination therapy with anti-PD1 and lenvatinib |
| Relevance |
Medical |
| Data types |
Proteomics, Metabolomics
|
| Organisms |
Homo sapiens
|
| Description |
Combination therapy using tyrosine kinase inhibitor like Lenvatinib and anti-programmed death-1 receptor (PD1) immunotherapy represents an effective systemic treatment of unresectable hepatocellular carcinoma (uHCC). However, patients' responses vary considerably. The molecular responsiveness of HCC patients deserves to be explored and prediction method of potential responders remains to be investigated. |
| Sample scope |
Multiisolate |
| Release date |
2024-07-27 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| National Natural Science Foundation of China (NSFC)
|
|
81572833
|
|
| National Natural Science Foundation of China (NSFC)
|
|
22074020
|
|
| National Natural Science Foundation of China (NSFC)
|
|
81871929
|
|
| National Natural Science Foundation of China (NSFC)
|
|
82072667
|
|
| Chen Guang Program of Shanghai Municipal Education Commission
|
|
19CG07
|
|
| Young Elite Scientists Sponsorship Program by CAST
|
|
2019QNRC001
|
|
|
|
| Submitter |
Cheng
Huang (huang.cheng@zs-hospital.sh.cn)
|
| Organization |
Zhongshan Hospital, Fudan University |
| Submission date |
2022-07-27 |
